Linus Health, a digital health company enabling early detection of Alzheimer’s and other dementias, announced today that its Core Cognitive Evaluation™ (CCE) solution has earned European Union (EU) Medical Device Regulation (MDR) Class IIa certification, indicating the cognitive impairment screening tool is safe, effective, and compliant with the governing laws.
HealthTech Insights: Hawkeye Group Announces the Launch of ClenchAlert Discrete Solution for Jaw Tension: A New Way to Combat Unconscious Teeth Clenching and Grinding
“The growth of dementia is a significant public health problem across the world,” said Linus Health Chief Medical Officer Alvaro Pascual-Leone, MD, PhD. “Earning EU class IIa MDR certification allows us to expand our offering in the EU beyond assessment to include clinical decision support, which is critical in supporting clinicians to navigate next steps, consider concrete actionable recommendations, and connect patients with the right care and clinical interventions that have been shown to delay or even prevent the onset of dementia due to Alzheimer’s disease or other causes.”
HealthTech Insights: BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines
Linus Health’s CCE gives primary care, specialists, and researchers a highly accurate digital cognitive assessment that is brief, easy to administer and brings visibility to early cognitive impairment. It combines objective analysis of cognitive performance with qualitative metrics to deliver brain health insights and a customized action plan to treat the disease.
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
